Australia: Lundbeck V Alphapharm

Last Updated: 29 June 2009

Article by Kerin Forstmanis, George Cameron and Emma Nelson

In a much anticipated decision the Full Federal Court has upheld the validity of Lundbeck's escitalopram patent for its 20 year term but would not allow an extension of the term.


Earlier this month the Full Federal Court published its decision in Lundbeck v Alphapharm1, an appeal from Lindgren J's decision in the Federal Court in June 2008. The appeal related to the validity and infringement of the patent for escitalopram, an anti-depressant marketed in Australia as Lexapro, as well as the extension of the patent term. To allow the launch of generic products shortly after the expiry of the patent's usual 20 year term on 13 June 2009, competitors had sought revocation of the patent on a number of invalidity grounds including lack of novelty and challenging the patents extension of term.

The proceedings have been of particular significance to those in the industry that seek to patent chemical compounds that are enantiomers. Enantiomers are isomers that are non-superimposable mirror images of each other, like a person's left and right hand. A mixture of two enantiomers in equal parts is known as a racemate or a racemic mixture. They can be distinguished from each other by the direction in which they rotate plane-polarised light. Depending on the direction of the light, enantiomers are designated as either (+) or (-). Escitalopram is the (+)-enantiomer of the racemate Citalopram, which was patented earlier and was one of the first antidepressants marketed in its particular class.

Construction of the Patent

Although the principles of claim construction are generally well accepted, the application of those principles can be difficult and may result in differing views about the scope of claims and as a consequence the validity and infringement of a patent.

On appeal, Bennett J (with Middleton J agreeing) stated that the primary issue to be resolved was, does (+)-Citalopram in claim 1 of the patent denote and claim the purified or isolated (+)-enantiomer, or the (+)-enantiomer whether alone or as part of a mixture, or the (+)-enantiomer as present in a racemate? Lindgren J had found that that claim 1 referred to the separated or isolated or pure (+)-enantiomer. Bennett J agreed with that aspect of the construction.

However, at trial Lindgren J also concluded that Claim 1 referred to Escitalopram that is at least 95% pure. Bennett J disagreed with the finding of purity, refusing to qualify the type of purity where none was made clear in the specification. As a demonstration that reasonable minds may differ, Emmett J dissented, and considered that Claim 1 related to the product or substance, the (+)-enantiomer, and there was nothing to suggest that it was to be isolated or of a particular property. This construction led to different conclusions about novelty.


At trial Lindgren J had held that an enabling disclosure in the context of a product claim means simply that the earlier disclosure must point unmistakably to the (+)-enantiomer of Citalopram as distinct from the racemate. It was held that there was no enabling disclosure and the product claims were valid. Bennett J considered that the use of the term "enablement" in Australia tended to cause some confusion between anticipation and sufficiency. Where a prior disclosure falls short of complete disclosure he said you must, with evidence from a person skilled in the art as to the terms of art and nature and extent of the disclosure, determine whether the prior disclosure is sufficient to enable the skilled addressee to perceive and understand the claimed invention.

There were 2 prior art documents relevant to the question of novelty. The first was the Citalopram patent. On appeal Bennett J agreed with Lindgren J, and found the Citalopram patent does not point specifically to the independent existence of the enantiomers, and does not disclose an invention which, if performed, would infringe the patent. Although the skilled addressee knew the racemate could be resolved into enantiomers there was nothing telling him or her to do so. The second document was a journal article that predicted one enantiomer would be more potent than the other but as it could not be determined which one without an inventive step there was accordingly no anticipation.


The infringement of the method of manufacture claim by the use of the same method differing only by the replacement of a substituent group that had no material change to the way the process worked was appealed. Bennett J (Middleton J agreeing) agreed with Emmett J that claim 6(b) was infringed, and overturned Lindgren J's primary decision because of the use of a particular chemical symbol in the claim instead of a symbol used elsewhere in the claims when substitution is permitted. The absence of that particular symbol in respect of the substitutable group signified the group was an essential integer of the method and substituting did not infringe the method.

Extension of the patent

Escitalopram is a pharmaceutical substance for the purposes of s70 of the Patents Act 1990 in relation to the extension of patent terms. As a claim for a substance in the formula described it is also a pharmaceutical substance per se and there is no question that it in substance falls within the scope of the claims. The other conditions to satisfy were that goods containing or consisting of Escitalopram must be included in the Australian Register of Therapeutic Goods (ARTG) and the period beginning on the date of the patent and the first regulatory approval date for the substance was at least 5 years.

The patent extension had initially been applied for and the period calculated on the basis that Escitalopram was the first good containing or consisting of that substance included on the ARTG. The question was, however, whether the first regulatory approval date for the substance was the inclusion of Citalopram on the ARTG because it contained Escitalopram in the racemate and the per se expression is only used in relation to the nature of the patent claims and should not be imported into other provisions. At trial Lindgren J considered this to be the case and on appeal Bennett J found his reasoning compelling. Bennett J expressed some reservation about the reliance of the decision of Wilcox J in Merck & Co Inc v Arrow Pharmaceuticals2 that a de minimus inclusion was sufficient.

In addition Bennett J held that the terms 'containing' and 'consisting' do not involve looking at the therapeutic effect of the pharmaceutical substance. Rather, it is said, it is a simple comparison of the pharmaceutical substance with the 'ingredients' of the goods on the ARTG. There is also no requirement to contrast effectiveness nor consider the purity.

Watch this space

Pending Lundbeck's special leave application to appeal to the High Court, The Full Court has granted Lundbeck a stay of the order for removal of the patent term extension from the Register. It is interesting to note that Lundbeck has also filed a new complete application for a Method of Preparation of Escitalopram on 6 February 2009.


1 H Lundbeck A/S v Alphapharm Pty Ltd [2009] FACFC 70

2 (2003) 59 IPR 226

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.